207 related articles for article (PubMed ID: 16376012)
1. The androgen receptor and prostate cancer invasion.
Bonaccorsi L; Muratori M; Marchiani S; Forti G; Baldi E
Mol Cell Endocrinol; 2006 Feb; 246(1-2):157-62. PubMed ID: 16376012
[TBL] [Abstract][Full Text] [Related]
2. Non-genomic effects of the androgen receptor and vitamin D agonist are involved in suppressing invasive phenotype of prostate cancer cells.
Bonaccorsi L; Marchiani S; Ferruzzi P; Muratori M; Crescioli C; Forti G; Maggi M; Baldi E
Steroids; 2006 Apr; 71(4):304-9. PubMed ID: 16289173
[TBL] [Abstract][Full Text] [Related]
3. Altered endocytosis of epidermal growth factor receptor in androgen receptor positive prostate cancer cell lines.
Bonaccorsi L; Nosi D; Muratori M; Formigli L; Forti G; Baldi E
J Mol Endocrinol; 2007 Feb; 38(1-2):51-66. PubMed ID: 17242169
[TBL] [Abstract][Full Text] [Related]
4. EGF receptor (EGFR) signaling promoting invasion is disrupted in androgen-sensitive prostate cancer cells by an interaction between EGFR and androgen receptor (AR).
Bonaccorsi L; Carloni V; Muratori M; Formigli L; Zecchi S; Forti G; Baldi E
Int J Cancer; 2004 Oct; 112(1):78-86. PubMed ID: 15305378
[TBL] [Abstract][Full Text] [Related]
5. The androgen receptor associates with the epidermal growth factor receptor in androgen-sensitive prostate cancer cells.
Bonaccorsi L; Muratori M; Carloni V; Marchiani S; Formigli L; Forti G; Baldi E
Steroids; 2004 Aug; 69(8-9):549-52. PubMed ID: 15288768
[TBL] [Abstract][Full Text] [Related]
6. Prostate cancer: a model of integration of genomic and non-genomic effects of the androgen receptor in cell lines model.
Bonaccorsi L; Nosi D; Quercioli F; Formigli L; Zecchi S; Maggi M; Forti G; Baldi E
Steroids; 2008 Oct; 73(9-10):1030-7. PubMed ID: 18358509
[TBL] [Abstract][Full Text] [Related]
7. Signaling mechanisms that mediate invasion in prostate cancer cells.
Bonaccorsi L; Marchiani S; Muratori M; Carloni V; Forti G; Baldi E
Ann N Y Acad Sci; 2004 Dec; 1028():283-8. PubMed ID: 15650253
[TBL] [Abstract][Full Text] [Related]
8. Dihydrotestosterone interacts with EGFR/MAPK signalling and modulates EGFR levels in androgen receptor-positive LNCaP prostate cancer cells.
Mukherjee B; Mayer D
Int J Oncol; 2008 Sep; 33(3):623-9. PubMed ID: 18695894
[TBL] [Abstract][Full Text] [Related]
9. Androgen up-regulates epidermal growth factor receptor expression and binding affinity in PC3 cell lines expressing the human androgen receptor.
Brass AL; Barnard J; Patai BL; Salvi D; Rukstalis DB
Cancer Res; 1995 Jul; 55(14):3197-203. PubMed ID: 7606741
[TBL] [Abstract][Full Text] [Related]
10. Androgen receptor and prostate cancer invasion.
Bonaccorsi L; Muratori M; Carloni V; Zecchi S; Formigli L; Forti G; Baldi E
Int J Androl; 2003 Feb; 26(1):21-5. PubMed ID: 12534934
[TBL] [Abstract][Full Text] [Related]
11. A cross-talk between the androgen receptor and the epidermal growth factor receptor leads to p38MAPK-dependent activation of mTOR and cyclinD1 expression in prostate and lung cancer cells.
Recchia AG; Musti AM; Lanzino M; Panno ML; Turano E; Zumpano R; Belfiore A; Andò S; Maggiolini M
Int J Biochem Cell Biol; 2009 Mar; 41(3):603-14. PubMed ID: 18692155
[TBL] [Abstract][Full Text] [Related]
12. Vasoactive intestinal peptide transactivates the androgen receptor through a protein kinase A-dependent extracellular signal-regulated kinase pathway in prostate cancer LNCaP cells.
Xie Y; Wolff DW; Lin MF; Tu Y
Mol Pharmacol; 2007 Jul; 72(1):73-85. PubMed ID: 17430995
[TBL] [Abstract][Full Text] [Related]
13. Steroid receptor regulation of epidermal growth factor signaling through Src in breast and prostate cancer cells: steroid antagonist action.
Migliaccio A; Di Domenico M; Castoria G; Nanayakkara M; Lombardi M; de Falco A; Bilancio A; Varricchio L; Ciociola A; Auricchio F
Cancer Res; 2005 Nov; 65(22):10585-93. PubMed ID: 16288052
[TBL] [Abstract][Full Text] [Related]
14. An AKT activity threshold regulates androgen-dependent and androgen-independent PSA expression in prostate cancer cell lines.
Paliouras M; Diamandis EP
Biol Chem; 2008 Jun; 389(6):773-80. PubMed ID: 18627304
[TBL] [Abstract][Full Text] [Related]
15. Secreted frizzled-related protein 4 inhibits proliferation and metastatic potential in prostate cancer.
Horvath LG; Lelliott JE; Kench JG; Lee CS; Williams ED; Saunders DN; Grygiel JJ; Sutherland RL; Henshall SM
Prostate; 2007 Jul; 67(10):1081-90. PubMed ID: 17476687
[TBL] [Abstract][Full Text] [Related]
16. TGF-beta signaling and androgen receptor status determine apoptotic cross-talk in human prostate cancer cells.
Zhu ML; Partin JV; Bruckheimer EM; Strup SE; Kyprianou N
Prostate; 2008 Feb; 68(3):287-95. PubMed ID: 18163430
[TBL] [Abstract][Full Text] [Related]
17. An androgen-independent androgen receptor function protects from inositol hexakisphosphate toxicity in the PC3/PC3(AR) prostate cancer cell lines.
Diallo JS; Péant B; Lessard L; Delvoye N; Le Page C; Mes-Masson AM; Saad F
Prostate; 2006 Sep; 66(12):1245-56. PubMed ID: 16705740
[TBL] [Abstract][Full Text] [Related]
18. Crosstalk between androgen receptor and epidermal growth factor receptor-signalling pathways: a molecular switch for epithelial cell differentiation.
Léotoing L; Manin M; Monté D; Baron S; Communal Y; Lours C; Veyssière G; Morel L; Beaudoin C
J Mol Endocrinol; 2007 Aug; 39(2):151-62. PubMed ID: 17693613
[TBL] [Abstract][Full Text] [Related]
19. Cell cycle regulator cdk2ap1 inhibits prostate cancer cell growth and modifies androgen-responsive pathway function.
Zolochevska O; Figueiredo ML
Prostate; 2009 Oct; 69(14):1586-97. PubMed ID: 19585490
[TBL] [Abstract][Full Text] [Related]
20. Androgen receptor controls EGFR and ERBB2 gene expression at different levels in prostate cancer cell lines.
Pignon JC; Koopmansch B; Nolens G; Delacroix L; Waltregny D; Winkler R
Cancer Res; 2009 Apr; 69(7):2941-9. PubMed ID: 19318561
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
